In our continued effort to discover novel PTP1B inhibitor with improved in vivo activity we attempeted to optimize our previously discoved lead compound by replacing the sulfonyl group with benzoyl group to yield compound II. Additional structural modifications were performed on compound II to yield a series of 24 aryl phenylthiazolyl phenylcarboxamides as potential PTP1B inhibitors. Among these compounds six compounds showed good PTP1B inhibitory activity in the order of compound 38 > 30 > 29 > 37 > 22 > 19. The plausible PTP1B binding site interaction of compound 38 showed favorable binding similar to known PTP1B binders and suggest its selectivity towards PTP1B. Compound 38 also showed promising antihyperglycemic, antidyslipidemic and insulin resistant reversal activities in vivo in STZ model and db/db mice model. Altogether, the compound 38 present an excellent candidate for future PTP1B targeted drug discovery.
Introduction
Protein-tyrosine phosphatase 1B (PTP1B) is a validated molecular target for the development of novel insulin-sensitizer agents addressing both Type 2 diabetes and obesity.
PTP1B catalyses dephosphorylation of the activated insulin receptor (IR) as well as Janus kinase 2 (JAK2) and thus negatively regulate insulin and leptin signalling pathways. [1] [2] [3] All of
Molecular docking
To gain an insight about essential structural requirements for ligand interactions at the active site of the PTP1B enzyme, the docking study was performed with the compound 38 at the binding site of PTP1B crystal structure (PDB ID: 2ZMM) [13] using the standard precision (SP) mode of Glide v6.7 of Schrödinger. [14] Ligands were prepared using LigPrep3.4 with Epik3.2 at pH 7.0. The lowest energy conformation among the largest populated cluster sharing common interactions was selected as the best binding pose for docked ligands. [15] 2.4. In vivo asaay
Anti-hyperglycemic activity
Streptozotocin induces anti-hyperglycemic activity screening was performed as reported in ref. 16 . Streptozotocin (STZ) is a broad spectrum antibiotic and selected to induce experimental diabetes because of its greater selectivity of β-cells, lower mortality and relatively longer half life (15 min) of STZ in the body. A solution of STZ (60 mg/kg) in 100 mM citrate buffer, pH 4.5 was prepared and calculated amount of the fresh solution dosed to overnight fasted rats intraperitoneally. Two days later baseline blood glucose was drawn from tail vein and glucose levels determined by glucostrips (Roche) to confirm the induction of diabetes. Rats having hyperglycaemia of the range of 270 and 450 mg/dL were considered as diabetic, selected and divided into groups of five animals each. One group used for normal control receives only vehicle (gumacacia) and this group was considered as diabetic control. The blood glucose measured at this time was termed the baseline (0 min) blood glucose. Rats of experimental groups were orally administered suspension of the desired test samples (made in 1.0% gum acacia) at desired dose levels and the biguanide derivative Metformin was used as standard antidiabetic drug and was always given at a dose of 100 mg/kg body weight orally to the experimental group. After 30 min of drug treatment, blood glucose level was again measured with glucometer. The blood glucose assessment were collected from tail vein just prior administration of test sample i.e. 0, 30, 60, 90, 120, 180, 240, 300 and 1440 min post test sample administration. After 300 min the STZ treated animals were allowed to feed over night to overcome drug induced hypoglycaemia. The animals were fed ad lib during 5 to 24h of experiments. The average fall in AUC (area under curve) in experimental group compared to control group was termed as % antihyperglycaemic activity. Statistical analysis was done by Dunnett's test.
db/db mice study
Male C57BL/Ks strain of mouse (db/db mouse) 10-12 weeks of age and around 40 ±3 g of body weight was procured from the animal colony of the Institute. The animals were housed four or five in a polypropylene cage in the animal house. The following norms were always followed for animal room environment: temperature 23 ± 2°C; humidity 50-60%; light 300 lux at floor level with regular 12h light cycle; noise level 50 decibel; ventilation 10-15 air changes per hour. After randomization into groups, the mice were acclimatized for 2-3 days in the new environment before initiation of experiment. Standard pellets were used as a basal diet during the experimental period.
Antihyperglycaemic and Antidyslipidemic activity assessment in C57BL/Ks strain of mouse (db/db mouse)
The animals were allocated into groups of 5 animals in each. Prior to start of the sample feeding, a vehicle training period was followed from day -3 to day 0 during which all the animals were given vehicle ( 1% gum acacia) at a dose volume of 10 mL/kg body weight. At day 0 the animals having blood group level between 350 to 500 mg/dL were selected and divided into three groups containing 5 animals in each. One group was considered as control group while the other group was treatment group. The experimental group was given suspensions of compound 154 and Pioglitazone at 30.0 and 10.0mg/kg body weight dose respectively. The control group was given an equal amount of vehicle. All the animals had free access to fresh water and normal diet. Random blood glucose of each mouse was checked daily at 10.00 pm. On day 10 and day 15 oral glucose tolerance (OGTT) test was performed to study the effect of compound on glucose tolerance. Blood has been withdrawn from the retroorbital plexus of mice eye for the estimation of lipid profile on DIALAB DTN-410-K and insulin level by CALBIOTECH Insulin ELISA Kit. Body weight of each animal was measured on alternate day for studying the effect of test sample on body weight. The skeletal muscle from each mouse were quickly excised at the end of experiment under light anesthesia and frozen at -80 o C until further use.
Oral glucose and intraperitoneal insulin and pyruvate tolerance test
Oral glucose and pyruvate tolerance test were performed on 12h fasted mice while insulin tolerance test was performed on 4h fasted mice. For OGTT mice were administered glucose 3.0 g/kg by gavages whereas for ITT and PTT, insulin (0.8U/kg) and pyruvate (2g/kg) was injected intraperitoneally, respectively. Blood samples were obtained via tail nick at 0, 30, 60, 90 and 120 min during OGTT and PTT while at 0, 15, 30, 60, 90 and 120 time points in ITT.
Glucose was measured with the One Touch Ultra glucometer (Accu-Chek Sensor, Roche Diagnostics).
Western blot analysis
Collected tissues and cells were homogenized into PBS containing 1% NP40, 5 mM EDTA, phosphatase inhibitors and protease inhibitors cocktail (lysis buffer). Samples were homogenized and incubated on ice for 15 min. Sample is then stored at -80ºC and thawed at 37ºC in waterbath. Sample was then centrifuged at 16000 rpm at 4ºC. Then supernatant was taken and quantified by Bradford assay. 40 μg protein (supernatant) of each incubation was resolved on SDS-PAGE, transferred to nitrocellulose membranes and probed with p-Akt and p-IRS1, Glut4 (Cell Signaling, MA, USA) and β-actin (Santa Cruz) was taken as the loading control. Immunoreactive bands were visualized by Enhanced Chemiluminescence according to manufacturer's instructions (GE Healthcare, UK). Protein expression was evaluated by densitometric analysis performed with Alpha DigiDoc 1201 software (Alpha Innotech Corporation, CA, USA). The same size rectangle box was drawn surrounding each band and the intensity of each was analysed by the program after subtraction of the background intensity.
Statistical analysis
The homeostatic model assessment (HOMA) was used to calculate relative insulin resistance as follows: [Fasting blood glucose (mg/dL) × Fasting serum insulin (µLU/mL)]/405. All statistical calculations were performed using Graph-Pad Prism version 3.02 for Windows (GraphPad Software). Statistical analysis was carried out by Students t test. Data was expressed as mean +SE. The criterion for statistical analysis was significant (*p<0.05), more significant (**p<0.01), highly significant (**p<0.01) and not significant (ns). The results are reported as mean values ± SEM.
Result and Discussion

Design and synthesis
PTP1B inhibitors containing thiazolyl and carboxyl group are known. [7, [9] [10] [11] 13] Therefore, we replaced sulfonyl moiety in the compound I by benzoyl group (region B) to afford compound II and to see its impact on the PTP1B inhibitory activity. (Fig. 1 ) In the next step the dihydrothiazolyl moiety in compound II (Region A) was substituted by 5phenylthiazolyl group to investigate if the phenyl ring can occupy better space/ interactions at the PTP1B enzyme active site than compound II. The systematic substitution by different groups around region B and C was carried out for getting more insight for SAR. This led us to synthesize a series of 24 substituted thiazolyl-N-phenyl-benzamide derivatives using procedure described in scheme1.
These synthesized compounds were evaluated for PTP1B enzyme inhibitory activity.
Compounds more than 50% inhibition at 10 µM concentration were further evaluated at five different concentrations to calculate their IC50 values ( Table1). Suramin (supplied in the enzyme activity kit) was used as a reference standard. The antihyperglycemic activity including PTP1B inhibitory activities of the thiazolyl-N-phenylcarboxamide derivatives are also presented in Table 1 .
Structure activity relationship (SAR) of compounds tested
Initial SAR studies were focused on C5 position of thiazolyl ring (R3) to explore if binding with the non-catalytic binding site of PTP1B could be enhanced. Therefore, as a starting point -Me group was inserted at R3 position and was kept constant to see the effect of R, R1, R2 and R4 substituent on the PTP1B inhibition. PTP1B inhibition (IC50 = 7.33 µM) respectively. 
Kinetics Measurements and Mechanism of Inhibition
Molecular Modeling Studies
In past our lab has successfully exploited structure-based computational approaches for understanding the structure-activity relationships. [13, [17] [18] [19] [20] To gain structural insight for further optimization, we constructed the 3D binding model of compound 38 to PTP1B using molecular docking. The binding analysis of the compound 38 revealed that 4-methoxyphenyl group linked with thiazolyl moeity was buried deep inside of a hydrophobic cavity formed by the residues Phe182, Ile219, and Ala217 which was further stabilized by its π-π interaction with Phe182, which in turn involved in the WPD loop closure. The thiazolyl group itself made π-π interaction with Tyr46 ( Fig. 3 ) which is commonly observed in many known PTP1B/inhibitor complexes. [14, [21] [22] [23] [24] The amino acid residues Arg47 and Asp48 which are close to the active site have been demonstrated important for selectivity of PTP1B because of the point mutation at this residue present in other phosphatases such as LAR (Asn48) and SHP-2 (Asn48). [25, 26] The phenyl acetyl group in the compound 38 showed potential to form hydrogen bond interaction with Asp48 and was in close contact to Arg47 which suggest its selectivity towards PTP1B.
However, more experiments need to be done to confirm this hypothesis. Water molecules also plays an important role in the stabilization of compound 38 through water mediated hydrogen bond interactions with amino acid residue Asp181 which is consistent with co-crystallized ligand used in this study. [14] Because of these multiple interactions, compound 38 positioned itself effectively at the PTP1B binding site to serve as a potent inhibitor. 
Streptozotocin rat model study
Based on the high PTP1B inhibitory activity in vitro, a limited number of compounds with more than 57% PTP1B inhibition were evaluated in vivo in Streptozotocin induced rat model (STZ). The table 1 discribes the effect of the ten selected compounds 17, 22, 26-30, 32, 37, 38 along with the standard compound Sodium orthovanadate on decline in blood glucose level of streptozotocin treated diabetic rats. Sodium orthovanadate was taken as positive control. It is evident from the results that out of the ten compounds tested, only one compound 38 showed a significant decline in blood glucose levels on streptozotocin induced diabetic rats. This decline in blood glucose level was around 22.8 % (p<0.05) and 23.7 % (p<0.01) during 0-5h and 0-24h, respectively ( Fig. 4A and B) . The standard drug sodium orthovanadate demonstrated maximum decline in blood glucose levels to the tune of 24.3 % (p<0.05) during 0-5h and 30.1 % (p<0.01) during 0-24h, post treatment respectively on STZ-induced diabetic rats at 100 mg/kg oral dose. The compounds 17, 22, 26-30, 32 and 37 though showed decline in blood glucose on STZ-induced diabetic rats at 100 mg/kg oral dose level as shown in Table   1 , however the effect was not found statistically significant in any of the cases except the compound 38 where the decline in blood glucose was observed around 23.7 % during 0-24 h ( Fig. 4) . Figure 4. A and B. Effect of compound 17, 22, 26-30, 32, 38 and Standard compound Sodium orthovanadate on blood glucose levels of the streptozotocin treated diabetic rats at various time intervals.
db/db mouse model study
Effect on hyperglycaemia
Compound 38 was further evaluated for antihyperglycaemic and antidyslipidemic activities in C57BL/KsJ-db/db mice ( Table 2) . Antihyperglycaemic activity was carried out in vivo using db/db mice by observing overall glucose lowering effect and also improvement on oral glucose tolerance at 30mg/kg for the period of 15 days. Pioglitazone was taken as positive control. It is evident from the Fig. 5A that compound 38 exerted its effect on blood glucose from day 5 while the significant effect was observed from day 7 and persisted till the end of the experiment, whereas, Pioglitazone (at the dose of 10mg/kg) significantly declined the random blood glucose from day 6 which persisted up to the end of the experiment as compared to vehicle treated control group. 
Effect on oral glucose tolerance
To observe the effect of drug on glucose tolerance, an OGTT (oral glucose tolerance test) To assess the whole-body insulin sensitivity, insulin tolerance test (ITT) was performed in vehicle, compound 38 and pioglitazone treated mice. It was found that compound 38 significantly improved the insulin sensitivity at 15 and 30 min after a bolus of 0.75 units of human insulin as shown in Fig. 5D and area under the curve (AUC) analysis also showed a 39.2% improvement in the insulin tolerance ( Fig. 5E) Fig. 5H and 5I. Homeostatic model assessment (HOMA) is a method used to quantify insulin resistance that is quantified on the basis of fasting blood glucose and fasting serum insulin level. The treatment with the compound 38 significantly improves the insulin resistance state by improving the HOMA-index by 66.6% (p<0.01) (Fig. 5J ).
Antidyslipidemic activity
Type 2 diabetes is known to be associated with several adverse cardiovascular risk factors, including obesity, hypertension and serum lipid abnormalities, characterized mainly by elevated serum total triglycerides and low levels of high-density lipoprotein (HDL) cholesterol.
Therefore, compound 38 was further tested for its effect on serum lipid profile. The treatment of the compound 38 restored the altered serum lipid profile as evident from the Fig.6 (A, B Excessive consumption of the food intake and body weight is responsible for the development of obesity and it can be directly linked to type 2 diabetes. Further observation on body weight during the antidiabetic activity in db/db mice study resulted in decrease of body weight in mice during the treatment of compound 38 (Fig. 6D ). 
Western blot analysis of p-IRSI in skeletal muscle of db/db mice
Further, the inhibition of PTP1B by compound 38 was evident by western blot analysis as shown in Fig.7A . The compound 38 effectively inhibited the PTP1B which is evident with increase of approximately 2.34 fold increase in the level of p-IRS-1 and 1.95 fold increase in the level of p-Akt, a downstream receptor of insulin signaling, while the reference drug rosiglitazone exhibited an increase of 3.21 and 2.52 folds in p-IRS1 and p-Akt respectively, as compared to vehicle treated control group. (Fig.7 B and C) . The activation of IRS1 and Akt by insulin resulted in the clearance of circulating blood glucose which is evident by the significant increase in protein level of Glut4 in skeletal muscle. In the present study, it was observed that the inhibition of PTP1B with compound 38 resulted in improved insulin signaling and glucose homeostasis with an increase of approximately 2.1-fold in Glut4 (Fig. 7D ). 
Conclusion
A series of aryl phenylthiazolyl phenylcarboxamide derivatives were synthesized and evaluated against PTP1B enzyme. Among the twenty-five synthesized compounds, six compounds showed good PTP1B inhibitory activity, namely 19 (IC50=7.0 μM), 22 (IC50=6.9 μM), 29 (IC50=6.3 μM), 30 (IC50=7.33 μM), 37 (IC50=6.9 μM) and 38 (IC50=5.8 μM). Docking studies showed that the interacting residues with compound 38 at the active site are consistent with known PTP1B inhibitors. Also interaction of compound 38 with Arg47 and Asp48 may attribute to its selectivity over other homologous phosphatases. Compound 38 also showed promising antihyperglycaemic, antidyslipidemic and insulin resistant reversal activities in vivo, in STZ model and db/db mice model. Thus, these studies may be helpful in developing novel PTP1B inhibitors with improved pharmacological properties.
